PharmaMar SA (PharmaMar)

Oncology Corporate Profile

HQ Location

Avda. De los Reyes, 1
Pol. Ind. La Mina-Norte, 28770-Colmenar Viejo Madrid, Sp

Company Description

PharmaMar is Grupo Zeltia's biotechnology subsidiary; it is a world leader in discovering, developing and commercializing marine-based drugs to treat cancer. Yondelis® is Spain's first anti-tumor drug. Yondelis is currently approved for STS in 34 countries outside the EEA, and in 10 of those countries for platinum sensitive ROC as well (including Brazil and Canada). Yondelis is approved for STS and platinum sensitive ROC in all 30 countries of the EEA; in Switzerland it is approved for STS. Yondelis® is also undergoing Phase II trials on breast and paediatric cancers. PharmaMar has five other compounds in clinical development: Aplidin®, Irvalec®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D program.

Website: http://www.pharmamar.com/

Brand Generic Indication
Yondelis®trabectedinYondelis® (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PM01183marine derived antitumoral agentBreast cancerIII
PM01183marine derived antitumoral agentOvarian cancerIII
Aplidin® / plitidepsinmarine derived antitumoral agent2nd line metastatic Multiple MyelomaIII
Yondelis® / trabectedinmarine derived antitumoral agent2nd line metastatic Ovarian cancerIIIJanssen
lurbinectedinRNA polymerase II prohibitorEwing´s SarcomaII
PM01183marine derived antitumoral agentLeukemiaII
PM01183marine derived antitumoral agentPancreatic cancerII
Aplidin® / plitidepsinmarine derived antitumoral agent2nd line metastatic Non-Hodgkin's Lymphoma (NHL)II
Yondelis® / trabectedinmarine derived antitumoral agentBreast cancerIIJanssen
Yondelis® / trabectedinmarine derived antitumoral agentPediatric cancerIIJanssen
PMO1183 (+ Doxorubicin)marine derived antitumoral agentSmall Cell Lung Cancer (SCLC)I
PM01183marine derived antitumoral agentVarious cancer typesI
PM060184marine derived antitumoral agentVarious cancer typesI
Irvalec®synthetic depsipeptideVarious cancer typesI

View additional information on product candidates here »

Source: http://www.pharmamar.com/

Recent News Headlines

There are no news items to display